摘要
本文对１７例Ⅲ期肺癌，测定了癌细胞ＤＮＡ含量，ＤＮＡ指数（ＤＩ），细胞增殖核抗原（ＰＣＮＡ）。１７例肺癌均给支气管动脉灌注化疗。小细胞肺癌（ＳＣＬＣ）和非小细胞肺癌（ＮＳＣＬＣ）分别缩小４８．８±３１．０％，３６．８±１７．１％（Ｘ±ＳＥ）。化疗后７例开胸手术６例切除肿瘤。ＳＣＬＣ和ＮＳＣＬＣ的中位生存期分别为３个月和８．５个月。在ＮＳＣＬＣ中，ＰＣＮＡ与肿瘤缩小范围呈负相关（ｒ＝－０．４７）；ＤＮＡ超四倍体百分比和ＤＩ存活时间呈正相关（（ｒ＝０．５１，ｒ＝０．５６）。ＳＣＬＣ则相关性差。结果表明，ＰＣＮＡ、ＤＡＮ和ＤＩ是ＮＳＣＬＣ判定疗效和预后的有用指标。
Abstract Deoxyribonucleic acid (DNA) content, DNA index (DI) and proliferating cell nuclear antigen (PCNA)of lung cancer cell were measured for 17 cases with stage Ⅲ of lung cancer. All 17 patients were treated by bronchial artery infusion (BAI). Median survival in the patients with SCLC was 3months, with NSCLC was 8. 5 months. There was negative correlation (r= - 0. 47) between PCNA and the arrangement of tumors shrunken; positive correlation (r= 0. 51, r = 0. 65) between percentage of DNA ultra-tetraploid, DI and survival period in NSCLC. There was a little correlation among indexes in SCLC.The results showed that PCNA, DNA and DI are useful index for deciding BAI effect and prognosis of NSCLC.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
1995年第5期292-293,295,共3页
Cancer Research on Prevention and Treatment
